Home
Subject List
Alphabetical List
Help
FAQ
Highlights
Deutsche Version
Quick Search
Advanced Search >>
Single Articles
View Shopping Cart
LogIn
Username
Password
Register Now
Thieme eJournals / AbstractContact Us
Article
Exp Clin Endocrinol Diabetes 2005; 113: 376-380
DOI: 10.1055/s-2005-865724

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York
 
 
Dihydrotachysterol Therapy for Hypoparathyroidism: Consequences of Inadequate Monitoring. Five Cases and a Review
 
I. Quack1, C. Zwernemann1, S. M. Weiner1, L. Sellin1, B. F. Henning1, R. Waldherr1, N. J. Büchner1, J. Stegbauer1, O. Vonend1, L. C. Rump1
1 Renal Divison, Marienhospital Herne, Ruhr University Bochum, Bochum, Germany

Abstract

Background: The half synthetic Vitamin D analogue dihydrotachysterol (DHT) is widely used for hypocalcaemic hypoparathyroidism following surgical removal of parathyroids. Such treatment generally initiated by surgeons right after surgery has to be continued in clinical practice. Unfortunately, the required careful monitoring of calcium metabolism is often lacking and as demonstrated may lead to life-threatening conditions. Patients and Methods: Here we report on five patients referred to our nephrology unit because of unknown impairment of renal function during therapy with DHT. All patients had clinical signs of hypercalcaemia. Since most symptoms are nonspecific they were not perceived by primary care physicians. In fact DHT treatment was continued for 4 - 50 years. In all cases calcium levels were determined after inadequate long intervals ranging from 3.08 to 4.97 mmol/l. Creatinine levels ranged from 277 to 365 µmol/l. All patients suffered from symptoms of severe hypercalcaemia, three of them needing intensive care unit treatment. Results: All patients were treated effectively with a regimen consisting of intravenous saline, a loop diuretic, and application of bisphosphonates. As confirmed by renal biopsy persisting alleviation of renal function was due to calcifications. After discontinuation of DHT therapy patients were safely switched to shorter acting vitamin D derivates maintaining a normal calcium level. Conclusions: In comparison to short acting vitamin-D derivates hypercalcaemic episodes with DHT appear to last longer and may therefore occur with higher incidence. A future option could be the use of synthetic parathyroid hormone (s-PTH) recently shown to be safe and effective. Nevertheless a customized therapy and careful monitoring is indispensable in any case to prevent irreversible organ damage.

Key words

Hypoparathyroidism - hypercalcaemia - kidney failure - vitamin D - dihydrotachysterol - parathyroid hormone

 
Full text (English) as
HTML (34 kb)  PDF (258 kb)
Table of Contents
Other Issues:
About This Journal
Editorial Information
Instructions for Authors
Subscribe Now
Service
Sample Issue (01/2009)
Recommend Article
Recommend Journal
Download Bibliographical Data
Bookmark Article
Delicious    Delicious



©
Thieme eJournals is a service of the Thieme Medical Publishers, Inc. and
Georg Thieme Verlag.
Georg Thieme Verlag KG Stuttgart New York. All rights reserved.
Impressum / Disclaimer